Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alnylam Pharmaceut (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,635,352
  • Shares Outstanding, K 100,170
  • Annual Sales, $ 89,910 K
  • Annual Income, $ -490,870 K
  • 36-Month Beta 2.68
  • Price/Sales 108.85
  • Price/Cash Flow N/A
  • Price/Book 5.44

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.01 +4.44%
on 04/06/18
149.73 -35.12%
on 03/21/18
-51.40 (-34.60%)
since 03/20/18
3-Month
93.01 +4.44%
on 04/06/18
153.99 -36.92%
on 03/20/18
-27.69 (-22.18%)
since 01/19/18
52-Week
49.19 +97.48%
on 04/21/17
153.99 -36.92%
on 03/20/18
+46.68 (+92.51%)
since 04/20/17

Most Recent Stories

More News
Technical Perspectives on Biotech Stocks -- Alnylam Pharma, Amgen, Amicus Therapeutics, and Ampio Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ALNY, AMGN, FOLD, and AMPE which can be accessed for free by signing up to www.wallstequities.com/registration....

FOLD : 14.21 (-2.94%)
ALNY : 97.48 (+1.34%)
AMGN : 171.39 (-0.89%)
Alnylam Pharmace Down 25.9% Since SmarTrend Downtrend Call (ALNY)

SmarTrend identified a Downtrend for Alnylam Pharmace (NASDAQ:ALNY) on March 28th, 2018 at $129.20. In approximately 3 weeks, Alnylam Pharmace has returned 25.90% as of today's recent price of $95.74....

ALNY : 97.48 (+1.34%)
Alnylam (ALNY) Reports Positive Data for RNAi Candidate

Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.

PTGX : 8.91 (+1.83%)
LGND : 166.76 (-1.09%)
CATB : 1.66 (-3.49%)
ALNY : 97.48 (+1.34%)
Alnylam Presents New Positive Clinical Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

--a^' Evidence of Enhanced Clinical Activity with Long-Term Treatment of up to 22 Months in Ongoing Phase 1/2 Open-Label Extension (OLE) Study, with an Over 90 Percent Decrease in Mean Annualized Porphyria...

ALNY : 97.48 (+1.34%)
Downtrend Call Working As Alnylam Pharmace Stock Falls 24.4% (ALNY)

SmarTrend identified a Downtrend for Alnylam Pharmace (NASDAQ:ALNY) on March 28th, 2018 at $129.20. In approximately 2 weeks, Alnylam Pharmace has returned 24.43% as of today's recent price of $97.63....

ALNY : 97.48 (+1.34%)
Look for Shares of Alnylam Pharmace to Potentially Rebound after Yesterday's 1.02% Sell Off

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $93.01 to a high of $97.22. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of...

ALNY : 97.48 (+1.34%)
EMA Accepts Regeneron/Sanofi's application for Dupixent

Regeneron and partner Sanofi's application for the label expansion of Dupixent has been accepted by the regulatory body in Europe. The application is also under review in the United States.

LGND : 166.76 (-1.09%)
ALNY : 97.48 (+1.34%)
REGN : 314.02 (-0.57%)
SNY : 39.96 (-0.50%)
Alnylam Falls on Pfizer's Rare Disease Drug Success

Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.

ALNY : 97.48 (+1.34%)
IONS : 48.49 (+5.76%)
REGN : 314.02 (-0.57%)
PFE : 36.63 (+0.27%)
Watch for Alnylam Pharmace to Potentially Rebound After Falling 16.64% Yesterday

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $97.01 to a high of $118.71. Yesterday, the shares fell 16.6%, which took the trading range below the 3-day low of...

ALNY : 97.48 (+1.34%)
Pfizer's Rare Disease Candidate Meets Endpoint in Phase III

Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.

ALNY : 97.48 (+1.34%)
IONS : 48.49 (+5.76%)
HLUYY : 56.6250 (-2.31%)
PFE : 36.63 (+0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies,...

See More

Key Turning Points

2nd Resistance Point 99.86
1st Resistance Point 98.02
Last Price 97.48
1st Support Level 95.01
2nd Support Level 93.84

See More

52-Week High 153.99
Fibonacci 61.8% 113.95
Fibonacci 50% 101.59
Last Price 97.48
Fibonacci 38.2% 89.22
52-Week Low 49.19

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar